Navigation Links
LifeCare Holdings, Inc. Announces Third Quarter Results
Date:11/14/2007

ary adjustments, which are not to exceed a cumulative average of 0.25% per annum, are tied to the Medicare long term acute care market basket inflation rate, as determined by the Centers for Medicare and Medicaid Services. As of September 30, 2007, the Milwaukee Landlord had made payments of $19.1 million to the Company towards the estimated total purchase price of $25.6 million for the Milwaukee Facility. No gain will be recognized from this transaction.

The initial term of the leases for these facilities will be 15 years, and the Tenant has one 15-year renewal option. The initial rent under the Amended Lease will be computed based on a predetermined spread over the rate of a 15-year U.S. Treasury Note and will be subject to an annual inflation adjustment. The Lease is an "absolute net lease" and contains customary covenants, representations and warranties. The Company and its subsidiary, LifeCare Hospitals of Milwaukee, Inc. and San Antonio Specialty Hospitals, LTD, entered into an Amended and Restated Unconditional and Continuing Lease Guaranty with the Landlord.

We entered into a separate Master Lease Agreement with Health Care REIT, Inc. on September 1, 2006, to acquire and develop hospital facilities. The first facility to be developed under this Master Lease is our Boise, Idaho facility, which is currently under construction. The total project cost of this facility is expected to approximate $18.5 million. Through September 30, 2007, we have incurred capital expenditure of $12.1 million for the facility, and Health Care REIT, Inc. has made payments to us approximating $10.5 million as reimbursement for these capital expenditures. This particular facility under this Master Lease will be accounted for as a lease financing obligation with the asset remaining capitalized upon completion.

CMS Fiscal 2008 Changes

Medicare Reimbursement Changes for Fiscal 2008

On May 1, 2007, CMS issued changes to the Medicare hospital payment system th
'/>"/>

SOURCE LifeCare Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine news :

1. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
2. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
3. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
4. Platinum Underwriters Holdings, Ltd. to Report Third Quarter 2007 Results on October 23, 2007
5. Air Methods Completes Acquisition of FSS Airholdings, Inc., Parent Company of CJ Systems Aviation Group, Inc.
6. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
7. China Shenghuo Pharmaceutical Holdings, Inc. Opens Showcase 12Ways(R) Chinese Herbal Beauty Salon in October
8. NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results
9. Duane Reade Holdings, Inc. to Report Third Quarter 2007 Financial Results
10. China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline
11. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... Conn., July 24 /PRNewswire/ -- People think it,s ...ffer many opportunities to eat right,and stay fit....t menu,selections, so if you order carefully your ...o: http://www.newscom.com/cgi-bin/prnh/20071212/N...mptation, you,ll want to stay,away from the cruise...
(Date:7/24/2008)... Greater access for people with disab...oad on ,Social Security disability system. , ...24, 2008 -- With the signing of the Americans with...n in the lives of people with disabilities and the... gained better access to methods that help them im...
(Date:7/24/2008)... A cleanroom manufacturing company ha...cleanrooms. The feature is a utility panel which ...hance the cleanroom appearance. , ...- Gerbig Engineering, a designer, fabricator and i...t they are now offering a utility panel for integr...
(Date:7/24/2008)... As America's baby boomers age, ...itions such as diabetes that necessitate the use o...t bracelet jewelry gives a generation attractive i...mation. , (PRWEB) July 24...tening health conditions can make a statement in m...
Breaking Medicine News(10 mins):Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Treat Yourself To a Healthy Cruise 2Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Treat Yourself To a Healthy Cruise 3Health News:Allsup Salutes 18th Anniversary of Americans with Disabilities Act 2Health News:Allsup Salutes 18th Anniversary of Americans with Disabilities Act 3Health News:Gerbig Engineering Announces Availability of Cleanroom Utility Panel 2Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 2Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 3
Life After Death: Organ Donation
...the first study to show that even mildly abnormal ...n elderly men undergoing major surgery," said Dr. ...dical Center and Brown University in Rhode Island....rovidence Veterans Affairs Medical Center and The ...
...s at the University of California, Riverside have ...nces, for two key proteins in the 'dragline silk' ...ad to a variety of new materials for industrial, m...dow spiders dragline silk is a standout compared t...
...-Hajam carefully placed the glass jars over the sl...n to pump out the air. In the ensuing vacuum , the... into the clear containers. "The Assyrians, the C... used to practice cupping to draw out the corrupt ...
Other Medicine News:Health News:Life After Death: Organ Donation 2Health News:Life After Death: Organ Donation 3Health News:Abnormality in the Red Blood Count Cell Poses High Risks 2Health News:Genetic Secrets Behind the Dragline Silk 2Health News:Ancient Healing Technique Gains New Popularity in Iraq 2
(Date:7/22/2008)... Two Regimens Including Lantus(R) and Apidra(R) R...nts with Type 2 Diabetes, Whatever the Algorithm ..., N.J., July 22 /- Results from the "... a Simple Algorithm to Carbohydrate,Counting for A...re,published in the American Diabetes Association,...
(Date:7/22/2008)...est Developed and Validated by Columbia University...s, Proprietary MicroRNA Technology, The Test Dif...ell Lung Cancer (NSCLC), Classifying Squamous-Cel... 96 Percent and Specificity of 90 Percent,This is ...RNAs, Sensitivity as Biomarkers for Accur...
(Date:7/22/2008)... A Pilot Study Suggests That Ekkyo,s New Approach ...tically Improve Scar Healing Physiology, MARSEILL...y known as,Heatwave Technology) a photomedicine co...ystems for skin scar prevention and reduction, ann...le in Lasers in Surgery and Medicine*,reporting th...
(Date:7/21/2008)... LONDON, July 21 /- The SEAS (Simva... investigated the effects of intensive,cholesterol...mg daily) and,ezetimibe (10 mg daily) in patients ...olves partial blockage of the aortic valve in,the ...people in Western,populations. Left untreated, it ...
Breaking Medicine Technology:Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4Clarient Reports First Quarter 2008 18095 1Clarient Reports First Quarter 2008 18095 2Clarient Reports First Quarter 2008 18095 3Clarient Reports First Quarter 2008 18095 4Clarient Reports First Quarter 2008 18095 5Clarient Reports First Quarter 2008 18095 6Clarient Reports First Quarter 2008 18095 7Clarient Reports First Quarter 2008 18095 8Patient Safety Authority Issues Annual Report for 2007 18091 1Patient Safety Authority Issues Annual Report for 2007 18091 2Patient Safety Authority Issues Annual Report for 2007 18091 3Patient Safety Authority Issues Annual Report for 2007 18091 4Patient Safety Authority Issues Annual Report for 2007 18091 5Patient Safety Authority Issues Annual Report for 2007 18091 6Patient Safety Authority Issues Annual Report for 2007 18091 7Patient Safety Authority Issues Annual Report for 2007 18091 8Patient Safety Authority Issues Annual Report for 2007 18091 9Patient Safety Authority Issues Annual Report for 2007 18091 10Patient Safety Authority Issues Annual Report for 2007 18091 11Patient Safety Authority Issues Annual Report for 2007 18091 12Patient Safety Authority Issues Annual Report for 2007 18091 13Patient Safety Authority Issues Annual Report for 2007 18091 14Patient Safety Authority Issues Annual Report for 2007 18091 15Patient Safety Authority Issues Annual Report for 2007 18091 16Patient Safety Authority Issues Annual Report for 2007 18091 17Patient Safety Authority Issues Annual Report for 2007 18091 18Sigma Aldrich Announces the Integration of Riedel De Haen Into Core Product Brands 5001 1Sigma Aldrich Announces the Integration of Riedel De Haen Into Core Product Brands 5001 2Sigma Aldrich Announces the Integration of Riedel De Haen Into Core Product Brands 5001 3Neurocrine Biosciences Reports First Quarter 2008 Results 1949 1Neurocrine Biosciences Reports First Quarter 2008 Results 1949 2Neurocrine Biosciences Reports First Quarter 2008 Results 1949 3Neurocrine Biosciences Reports First Quarter 2008 Results 1949 4Neurocrine Biosciences Reports First Quarter 2008 Results 1949 5Neurocrine Biosciences Reports First Quarter 2008 Results 1949 6Neurocrine Biosciences Reports First Quarter 2008 Results 1949 7Neurocrine Biosciences Reports First Quarter 2008 Results 1949 8
... - Algeta ASA (OSE: ALGETA), the,Norwegian cancer ...lash;yvind Bruland, of the Norwegian Radium Hospit...ter and Discussion entitled,"Radium-223 in the tr...cancer (HRPC): Results from a randomized,placebo-...ty of,Clinical Oncology,s annual meeting (1-5 June...
...NESS WIRE)--May 29, 2007 - Gilead,Sciences, Inc. (...R-CF1 (CP-AI-007) study of aztreonam lysine for in...ibrosis (CF) who have,pulmonary Pseudomonas aerugi...oint of change at Day 28 from baseline in respirat...uestionnaire-Revised,(CFQ-R), a patient-reported o...
Other Medicine Technology:Algeta to Present Phase II Clinical Study Data for Alpharadin in,Prostate Cancer at ASCO 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5
For the direct, colorimetric determination of calcium in human serum or urine. Linearity: 20 mg/dl.
Alanine Aminotransferase (ALT) reagent is used for the quantitative determination of alanine aminotransferase (Glutamate pyruvate transaminase, SGPT) in human serum.
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution.
For the determination of urea nitrogen in human serum.
Medicine Products: